US12295987 — Method of using a GIP/GLP1 co-agonist for diabetes
Method of Use · Assigned to Eli Lilly and Co · Expires 2041-12-30 · 16y remaining
What this patent protects
This patent protects methods of treating type 2 diabetes using a specific dosing regimen of a GIP/GLP-1 peptide.
USPTO Abstract
Provided herein are methods of treating type 2 diabetes (T2D) using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 10:1 GIP to GLP-1. Also provided herein are methods of treating T2D using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 5:1 GIP to GLP-1.
Drugs covered by this patent
- Mounjaro (TIRZEPATIDE) · Eli Lilly
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4192 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4192 |
— | Mounjaro |
U-4192 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4192 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4192 |
— | Mounjaro |
U-4192 |
— | Mounjaro |
U-4192 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
U-4193 |
— | Mounjaro |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.